Most people on GLP-1 never get a single lab drawn. That is fine until something quiet (B12 dropping, kidney function shifting, lipase climbing, testosterone improving without your doctor noticing) actually matters. Here is exactly what to test, when, and what the numbers mean.
🔑 Key Takeaways
- FDA does not require any specific labs to start GLP-1, but a baseline panel is the difference between knowing what your body is doing and guessing.
- The core baseline panel: HbA1c, fasting insulin, lipid panel, CMP (kidney + liver + electrolytes), TSH, B12, lipase, CBC. Optional: hsCRP, calcitonin if MEN2 family history, fasting C-peptide.
- The follow-up cadence: 8 to 12 weeks after starting, then every 3 to 6 months for the first year, then every 6 to 12 months once stable.
- Testosterone matters most for men. About half of obese men have total T below 300 ng/dL. GLP-1 raises total T by roughly 18% on average through weight loss, lower aromatase activity, and reduced visceral fat. The effect is mostly secondary, not direct.
- The men who benefit most: BMI over 30, fatigue, low libido, baseline total T 200 to 350 ng/dL. By 18 months on GLP-1, roughly 77% reach a healthy T range.
- Specific values matter more than the trend: hsCRP under 1, B12 over 400 pg/mL, eGFR over 60, ALT under 45 (men) or 35 (women), lipase under 3x ULN, total T over 350 ng/dL.
- Red flags that warrant immediate action: lipase over 3x ULN (pancreatitis), eGFR drop over 15 points, ALT over 2x baseline, sudden vision change, severe abdominal pain.
- You can order most of these yourself through direct-to-consumer labs (Quest, Labcorp on demand, Walk-In Lab, ChooseHealth). Useful when you do not want to wait for a clinic visit.
This page is the lab playbook for anyone on GLP-1. Baseline panel, follow-up schedule, what each value means, what to do when something looks off, and the specific testosterone trajectory for men.
The Baseline GLP-1 Lab Panel
What to draw before your first injection.
| Test | Why | Target / normal range |
|---|---|---|
| HbA1c | Glycemic baseline, dose decision | Under 5.7% optimal; 5.7 to 6.4% prediabetes; 6.5%+ diabetes |
| Fasting glucose | Acute glycemic state | Under 100 mg/dL optimal |
| Fasting insulin | Insulin resistance baseline | Under 10 µIU/mL optimal; over 25 strong IR |
| Lipid panel (LDL, HDL, TG, total) | Cardiovascular risk + tracking improvement | LDL under 100, HDL over 40 (men) or 50 (women), TG under 150 |
| Comprehensive metabolic panel | Kidney (creatinine, eGFR, BUN), liver (ALT, AST), electrolytes | eGFR over 60, ALT under 45 (men) or 35 (women) |
| TSH (and Free T4 if hypothyroid) | Thyroid function, dose interaction with levothyroxine | 0.5 to 4.5 mIU/L |
| B12 (serum) | Baseline reference for any future deficiency | Over 400 pg/mL optimal |
| Lipase | Pancreatitis baseline | Under 60 U/L typical; over 3x upper limit = significant |
| CBC | General hematologic baseline | WBC, RBC, hemoglobin, hematocrit, platelets within range |
Optional add-ons
- hsCRP (high-sensitivity C-reactive protein) for tracking inflammation. Target under 1 mg/L. GLP-1 typically drops this 30 to 40% over 6 months.
- Calcitonin if family history of medullary thyroid cancer or MEN2 syndrome. GLP-1 carries a boxed warning about C-cell tumors (rodent data, not human-confirmed). Most users do not need this; high-risk family history users do.
- Fasting C-peptide if there is any question about insulin production capacity (relevant for distinguishing type 2 from late-onset type 1).
- Vitamin D, ferritin, magnesium for nutritional status, especially in women and those on restrictive diets.
- Total and free testosterone (men) as a baseline, especially if any low-T symptoms are present.
- SHBG and estradiol (men) alongside testosterone for full picture.
The GLP-1 Follow-Up Schedule
The "every 3 to 6 months" cadence covers most users.
| Time point | What to test | Why |
|---|---|---|
| Baseline | Full panel above | Reference point |
| 8 to 12 weeks (first stable dose) | HbA1c (if diabetic), CMP, lipase, hsCRP | Catch acute changes early |
| 6 months | Full repeat panel | Track response, dose adjustment |
| 12 months | Full panel + B12 + testosterone (men) | Annual reassessment |
| Annually thereafter | Full panel | Long-term safety |
| Symptom-driven | Whatever fits the symptom | Pancreatitis, severe pain, vision change, severe fatigue |
GLP-1 and Testosterone: What Happens for Men
The testosterone effect is one of the most under-discussed benefits.
About half of obese men (BMI over 30) have total testosterone below 300 ng/dL, the AUA threshold for hypogonadism. Most are not on TRT. Many do not know.
What changes on GLP-1, based on the meta-analysis of 4 trials (around 219 patients, mean age 47):
- Total testosterone rises by about 18% (322 to 380 ng/dL average)
- Bioavailable testosterone rises significantly (the most physiologically meaningful)
- Free testosterone rises about 17% on average, though the change is on the edge of statistical significance
- SHBG changes are minimal (no significant shift in most studies)
- Estradiol tends to drop modestly (less aromatase activity from less fat tissue)
- By 18 months on GLP-1, about 77% of obese men with low T reach the healthy range
Mechanism, simplified
The testosterone improvement is mostly secondary, not direct. GLP-1 does not bind the testes or stimulate testosterone production. What it does is reduce visceral fat. Visceral fat tissue contains aromatase, the enzyme that converts testosterone to estrogen. More fat means more conversion, lower T. Less fat means less conversion, higher T. The drug also improves insulin sensitivity, which raises SHBG slightly and reduces metabolic inflammation, both of which support hypothalamic-pituitary-gonadal axis function.
The expected timeline
| Time point | Expected total T change | Notes |
|---|---|---|
| Baseline | (reference) | About 50% of obese men under 300 ng/dL |
| 3 months | +5 to +10% | Some users notice early energy and libido improvement |
| 6 months | +10 to +15% | Most measurable rise begins around significant weight loss |
| 12 months | +15 to +20% | Approaching meta-analysis average |
| 18 months | +15 to +25% | ~77% reach healthy range; effect plateaus with weight stabilization |
GLP-1 plus TRT
The combination is safe and is sometimes used deliberately. Drugs.com confirms no clinically significant interaction. If you are on TRT and start GLP-1, expect total T to keep rising as visceral fat drops; monitor hematocrit (TRT raises it; weight loss does not lower it as predictably) and PSA. Some men can lower their TRT dose as endogenous T improves.
The Lab Values That Actually Move on GLP-1
What goes up, what goes down, and what stays flat.
| Marker | Direction | Typical magnitude | Why it matters |
|---|---|---|---|
| HbA1c | Down | 0.5 to 1.5% | Glycemic control |
| Fasting glucose | Down | 10 to 30 mg/dL | Daily glucose |
| Fasting insulin | Down | Often halves over 6 to 12 months | Insulin resistance reversal |
| LDL cholesterol | Down | 5 to 15% | CVD risk |
| Triglycerides | Down | 15 to 30% | Pancreatitis risk reduction, CVD |
| HDL | Slight up or flat | 0 to 5% | Less responsive than LDL/TG |
| ALT | Down | 20 to 40% in those with elevated baseline | Liver fat reversal |
| hsCRP | Down | 30 to 40% | Systemic inflammation |
| eGFR | Stable or slight up | 0 to 5 ml/min | Kidney function. Drop of over 15 points warrants attention. |
| Creatinine | Stable | Minor | Watch for sudden rise (dehydration risk) |
| Lipase | Mild rise to small drop | Variable | Concerning only over 3x ULN |
| B12 | Stable to down | Variable | Falls if intake drops significantly |
| Total testosterone (men) | Up | 15 to 25% over 12 to 18 months | Mostly secondary to weight loss |
| Estradiol (men) | Down | Modest | Less aromatase activity |
| Calcitonin | Stable | None | Watch only with MEN2 history |
Red Flags: When Labs Tell You to Act
| Finding | What to do |
|---|---|
| Lipase over 3x upper limit | Stop GLP-1. Get evaluated for pancreatitis. |
| ALT over 2x baseline | Hold GLP-1, repeat in 2 weeks, get hepatology consult if persistent |
| eGFR drop over 15 points | Hydration check, dose pause, repeat in 1 to 2 weeks |
| HbA1c rising despite GLP-1 | Adherence check, dose increase consideration, evaluate other drivers |
| B12 under 250 pg/mL | Confirm with MMA. Start supplementation. |
| Sudden severe abdominal pain | Emergency room. Pancreatitis until proven otherwise. |
| Sudden vision change | Same-day ophthalmology. NAION is time-sensitive. |
| Calcitonin rising in MEN2 family history | Endocrinology evaluation, consider stopping GLP-1 |
Direct-to-Consumer Lab Options
You can order most of this yourself.
For users who want labs without a clinic visit, several direct-to-consumer options offer GLP-1-specific panels that approximate the panel above. Pricing typically runs $80 to $250 depending on the panel size.
- Labcorp OnDemand (operates the labs that most clinics use)
- Quest Direct (the other major lab network)
- Walk-In Lab
- Ulta Lab Tests
- InsideTracker (more biomarker-focused with interpretation)
- Choose Health (curates panels for medication users)
Order, draw at a partner location (Labcorp or Quest), get results in 1 to 5 days. Bring the printout to your prescriber if anything looks off.
Frequently Asked Questions
Medical disclaimer. This article is informational only and does not replace individualized medical advice. Lab interpretation, especially in the context of red flags or significant changes from baseline, should be done by a qualified clinician. Decisions about starting, dosing, switching, or stopping GLP-1 medications should be made with the prescribing clinician.